Medicine Information

Generating Pharmaceutical Sales before Marketing Authorization


When a patient has a serious illness and there is no approved drug available, the physician may want to try one which has not been authorized for marketing by national health authorities but has shown promise in clinical trials. European Named Patient Programs, like US compassionate use programs, offer physicians access to pharmaceuticals which have not yet been licensed. However, there is one important difference: in Europe an unlicensed drug can be reimbursed. This presents drug-makers with an opportunity to generate revenues while development is still in-progress.

Significant Revenues Are Possible

The additional revenues can be considerable. For example, Pharmion, a US based company focusing on Oncology and Hematology reported dramatic increases in its Thalidomide sales from $1.9 million in 2Q '03 to $15.3 million in 2Q '04, primarily due to named patient sales in Europe for Multiple Myeloma. Thalidomide sales accounted for approximately 75% of Pharmion's total revenues for the first half of 2004, according to company sources, and were generated while the product awaits marketing approval for this indication. Before receiving European Marketing Approval, Shire's Argylin® for essential thrombocythaemia generated about 5% of its total sales from its European named patient program.

Though thalidomide and Agrylin were licensed in the USA for some indications, pharmaceutical companies do set-up named patient programs and receive full reimbursement for drugs that are not licensed for any indication in any market. Examples include: Insmed's SomatoKine® authorized for named patient use for Primary Lateral Sclerosis, Growth Hormone Insensitivity Syndrome (GHIS) and Severe Insulin Resistance and Protherics' ViperaTAb? authorized for named patient use for adder snake bites.

Other Benefits of Named Patient Programs

A named patient program can speed uptake after official launch. Physicians, who have had experience before launch, via clinical trials or named patient programs, often become early adopters and references for other physicians once the drug is freely circulating.

Named patient programs, like US compassionate use programs, can increase good-will toward the company because they simplify the process of gaining access for patients in critical need. Smaller companies often can not afford the administrative time and costs of shipping drugs around the world before launch. This can lead to frustration and resentment towards a company that many physicians will remember long after a drug is officially on the market. Creating a formal channel eliminates the unfortunate need of denying requests and risking ill-will later.

A named patient program should be considered an important part of a pre-launch program. It increases awareness to a pharmaceutical's existence, creates excitement, generates good-will and speeds penetration of the product after launch.

Frequent Communication is Necessary

If one of the objectives is to generate revenues, setting up a named patient program is just the beginning. In order to achieve success, physicians need to be aware of the product and what they need to do to get it. Typical methods of informing physicians, such as sales rep visits and ads, may not be appropriate because a license is necessary to market a drug. While physicians are used to simply writing a prescription and being done with it, named patient programs require paper-work that some find tedious. Therefore the company needs to create an appropriate communication plan and work closely with the targeted medical community to keep them informed and simplify the process.

Issues to Consider

You have decided to make a named patient program part of your pre-marketing plan, what now?

? Administration: Do you "go it alone" or work with a company that is experienced at administering named patient programs?

There are several experienced organizations that can assist your company by gaining approval, setting-up the program, doing administration and taking care of physical distribution. If your organization is well resourced and has a pipe-line of products that will require named patient programs, it might be worthwhile acquiring the expertise internally. However, if you have few appropriate products or a stream-lined organization, it is probably best to consider outsourcing.

? Communication: You've set up the program, how do you optimize it?

If you do not have an experienced European marketing group, an organization that is familiar in sales and marketing of pharmaceuticals in Europe can help you to maximize participation in the named patient program. A communication plan, if properly developed and implemented can increase product awareness, but communication concerning an unlicensed product must be done appropriately. This plan should ensure that your entire target group:

? Is fully aware of the product AND the program

? Knows what needs to be done to take advantage of the program

? Has an advocate available to guide them through the process

The Author, Dr Gene Emmer, is President of Med Services Europe B.V., a European-based consultancy focused on Sales, Marketing and Business Development of Pharmaceutical, Diagnostic and Medical Products. http://www.MedServicesEurope.com +31648566707


MORE RESOURCES:
This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news


New York Times

Using Medicine and Science to Improve the Quality of Life
New York Times
To Ms. Onie, that story offers an example of what is wrong with America's health care system: It can be so focused on medicine that it misses the social issues that really drive health. For more than 20 years since she co-founded the nonprofit Health ...



Forbes

RoosterBio Is Targeting $67 Billion Global Regenerative Medicine Market
Forbes
When you hear about “Regenerative Medicine,” it is often about stem cell therapy and tissue engineering. These two innovations alone are driving the large industry market estimates ranging from four billion dollars to $67 billion. The National ...



Daily Record-News

New Ellensburg family practice doctor emphasizes functional medicine
Daily Record-News
“Functional medicine, a lot of it is working through nutrition, discovering and trying to pinpoint any underlying cause for the disease, rather than just treating it with medications,” Elperin said. “Functional medicine is a way to bring the body back ...



Business Insider

Trump gave Kim Jong Un a taste of his own medicine — and now North Korea is begging to save the summit
Business Insider
President Donald Trump on Thursday pulled a classic North Korean negotiating move by canceling his planned summit with Kim Jong Un. Within 12 hours of the cancellation, North Korea backtracked on threats to "reconsider" the summit. It now says it will ...

and more »


PhillyVoice.com

Why medicine leads the professions in suicide, and what we can do about it
PhillyVoice.com
Earlier this month, one of us visited a prominent U.S. medical school to give a lecture on the topic of burnout and how physicians can find more fulfillment in the practice of medicine. Sadly, that very day, a fourth-year medical student there took her ...



SCNow

Florence Family Medicine aims for personal touch
SCNow
FLORENCE, S.C. — Florence Family Medicine employees joined ambassadors from the Greater Florence Chamber of Commerce to hold a ribbon cutting Thursday morning. Florence Family Medicine, at 315 N. Beltline Drive, Suite E, provides primary care ...



Lifehacker Australia

Your Baby's Teething Medicine Could Be Dangerous
Lifehacker Australia
If you're a parent, you've been there. All the rocking, patting and rounds of “Old McDonald” in the world won't stop your baby's misery. After weeks of sleepless ...

and more »


Futurity: Research News

Don't give opioid cough medicine to kids. Here's why
Futurity: Research News
The findings support recent US Food and Drug Administration (FDA) restrictions on prescription hydrocodone- and codeine-containing cough medicines for children and suggests that opioids in general should not be prescribed for kids' coughs and colds.



The Guardian

Mambas, medicine and one girl's race to survive Kenya's biting problem
The Guardian
In a country where snakebite treatment is costly, hard to come by and often inadequate, Rashid Chiti feared the worst when his daughter was bitten by a black mamba. Now the World Health Assembly is about to pass a resolution that might finally boost ...



KETV Omaha

CHI, Nebraska Medicine team up to stop violence - KETV.com
KETV Omaha
Two local health systems are teaming up to prevent violence in the metro. CHI Health and Nebraska Medicine are working together with Omaha violence ...

and more »

Google News

home | site map | Dr. Thad Thomas
© 2006